Skip to main content
Premium Trial:

Request an Annual Quote

MetriGenix Acquires GeneXP to Pool Gene Expression-Based Biomarker Efforts

NEW YORK, June 7 (GenomeWeb News) - MetriGenix of Toronto has acquired GeneXP Biosciences of Woburn, Mass., MetriGenix said today.

 

Financial and other terms of the acquisition were not disclosed.

 

Both companies have been developing gene expression-based biomarkers for different diseases using microarray technology. The acquisition will compbine their biomarker development activities "into a single portfolio that can be managed and developed faster and more efficiently," said Michael Cohen, the former president of GeneXP and new CEO of MetriGenix, in a company statement.

 

The combined company will continue to operate in Torontoand Woburn.